



**Supplemental Figure 1.** (A) PBN for platelets, (B) PBN for neutrophils and (C) TLC with respect to the patient group with bone marrow involvement (BMI) and the patient group without bone marrow involvement (no BMI). Patients were treated with  $^{90}\text{Y}$ -ibritumomab tiuxetan (▲) or  $^{131}\text{I}$ -tositumomab (□).

**Supplemental Table 1.** Actual and predicted platelet count as well as actual and predicted thrombocytopenia grade. Patients # 1 to 18 were treated with <sup>131</sup>I-tositumomab and patients # 19 to 32 were treated with <sup>90</sup>Y-ibritumomab tiuxetan. Both variables, TLC and BSL, used in the toxicity prediction model are reported as well.

Patient #	Time since last chemotherapy in months (TLC)	Platelet count ( $\cdot 10^3$ per mm <sup>3</sup> )			Thrombocytopenia grade	
		Baseline (BSL)	Actual at nadir	Predicted at nadir	Actual at nadir	Predicted at nadir
1	7	197	75	46	2	3
2	21	213	194	132	1	1
3*	3	195	4	24	4	4
4	7	220	31	54	3	2
5	3	416	35	50	3	3
6	19	137	68	84	2	1
7	20	104	64	66	2	2
8*	10	182	37	61	3	2
9	26	79	65	64	2	2
10	7	85	3	21	4	4
11	3	67	14	8	4	4
12	16	190	122	95	1	1
13	7	260	22	64	4	2
14	10	164	43	55	3	2
15	6	123	62	24	2	4
16*	8	159	26	44	3	3
17*	7	246	183	55	1	2
18	9	266	44	81	3	1
19	15	106	62	50	2	3
20	1	114	6	7	4	4
21	12	208	104	80	1	1
22*	10	177	7	60	4	2
23	3	198	21	24	4	4
24*	3	237	44	27	3	3
25*	6	535	137	111	1	1
26	5	388	78	69	1	2
27	11	177	38	65	3	2
28	1	261	28	14	3	4
29	17	138	54	77	2	1
30	3	247	37	29	3	3
31	3	259	43	30	3	3
32	5	187	9.1	35	4	3

\* Patient with presence of bone marrow involvement (BMD)

**Supplemental Table 2.** Actual and predicted ANC as well as actual and predicted neutropenia grade. Patients # 1 to 18 were treated with <sup>131</sup>I-tositumomab and patients # 19 to 32 were treated with <sup>90</sup>Y-ibritumomab tiuxetan. Both variables, TLC and BSL, used in the toxicity prediction model are reported as well.

Patient #	Time since last chemotherapy in months (TLC)	ANC per mm <sup>3</sup>			Neutropenia grade	
		Baseline (BSL)	Actual at nadir	Predicted at nadir	Actual at nadir	Predicted at nadir
1	7	5,590	4,290	1,500	1	2
2	21	4,720	3,910	2,740	1	1
3*	3	1,530	800	260	3	4
4	7	3,290	170	960	4	3
5	3	2,460	210	480	4	4
6	19	2,370	1,260	1,360	2	2
7	20	2,230	1,920	1,230	1	2
8*	10	4,830	540	1,760	3	1
9	26	3,180	2,240	2,370	1	1
10	7	1,860	100	550	4	3
11	3	1,885	700	340	3	4
12	16	3,230	2,040	1,580	1	1
13	7	4,690	770	1,360	3	2
14	10	2,540	800	910	3	3
15	6	5,220	1,700	1,350	1	2
16*	8	4,720	1,030	1,470	2	2
17*	7	4,080	1,990	1,130	1	2
18	9	5,370	648	1,820	3	1
19	15	4,010	1,590	1,920	1	1
20	1	3,350	44	520	4	3
21	12	2,630	880	1,070	3	2
22*	10	2,579	170	940	4	3
23	3	3,260	1,070	590	2	3
24*	3	3,370	500	650	4	3
25*	6	7,550	3,200	1,930	1	1
26	5	11,080	1,530	2,680	1	1
27	11	2,220	343	860	4	3
28	1	2,500	665	330	3	4
29	17	4,240	2,080	2,230	1	1
30	3	4,250	786	810	3	3
31	3	5,050	1,380	930	2	3
32	5	3,710	634	890	3	3

\* Patient with presence of bone marrow involvement (BMD)